封面
市场调查报告书
商品编码
1592051

克拉伯氏症治疗市场:按疾病类型、治疗方法和分销管道划分 - 全球预测 2025-2030 年

Krabbe Disease Treatment Market by Disease Type (Infantile, Late-onset), Treatment (Anticonvulsant Agents, Bone Marrow Transplantation, Muscle Relaxer Drugs), Distribution Channel - Global Forecast 2025-2030

出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

克拉伯疾病治疗市场2023年估值为17.2亿美元,预计到2024年将达到18.3亿美元,复合年增长率为6.49%,到2030年预计将达到26.8亿美元。

克拉伯氏症是一种罕见且往往致命的遗传性疾病,影响神经系统,由于其复杂性和有限的治疗选择而日益成为医学研究的焦点。使用的主要治疗方法是造血干细胞移植(HSCT)、酵素替代疗法和基因疗法,但由于这些治疗方法的有效性和可用性有限,市场需求仍然很高。这种未满足的需求,加上生物技术和医学的进步,激发了人们对开发更有效、更容易获得的解决方案的兴趣。关键的成长要素包括疾病意识和诊断的提高、基因研究的进步以及政府对罕见疾病的支持政策。最新的机会在于 CRISPR 等基因编辑技术和新型药物配方的进步,为突破性治疗和改善患者的生活品质提供了潜力。然而,这个市场面临重大挑战,包括高昂的研发成本、与罕见疾病相关的监管复杂性以及有限的患者群。为了克服这些限制,公司可以专注于联合研究计划以及与学术机构的伙伴关係。个人化医疗的创新倡议,特别是根据基因谱进行个人化治疗,是一个令人兴奋的领域,具有成长和差异化的潜力。市场的性质仍然充满挑战和前景,其特点是技术快速进步以及物流和财务障碍较高。成功的市场进入和领导地位需要对研发进行策略性投资,对新的监管要求做出敏捷响应,并且对患者的旅程有深入的了解,以熟练地解决关键的未满足的需求。持续进行市场研究以监测技术趋势、政策转变和竞争倡议对于克拉伯氏症治疗市场的定位和持续成长至关重要。

主要市场统计
基准年[2023] 17.2亿美元
预测年份 [2024] 18.3亿美元
预测年份 [2030] 26.8亿美元
复合年增长率(%) 6.49%

市场动态:揭示快速发展的克拉伯氏症治疗市场的关键市场洞察

克拉伯氏症治疗市场正因供需的动态交互作用而转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险,同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 克拉伯氏症在全球的盛行率不断上升
    • 基因治疗和干细胞移植研究的增加
    • 政府和私人努力提高对遗传疾病的认识
  • 市场限制因素
    • 克拉伯氏症的治疗高成本
  • 市场机会
    • 克拉伯氏症的诊断和治疗进展
    • 扩大克拉伯氏症研究的有利资金状况
  • 市场问题
    • 克拉伯氏症检测与治疗的伦理问题

波特五力:开拓克拉伯氏症治疗市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势,解决弱点并避免潜在的挑战,从而确保更强大的市场地位。

PESTLE分析:了解克拉伯氏症治疗市场的外在影响

外部宏观环境因素在塑造克拉伯氏症治疗市场的绩效动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素,公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化,并为他们做出积极主动的决策做好准备。

市场占有率分析:了解克拉伯氏症治疗市场的竞争格局

对克拉伯病治疗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势,为供应商提供了製定策略决策所需的洞察力,以应对日益激烈的竞争。

FPNV 定位矩阵:克拉伯氏症治疗市场供应商的绩效评估

FPNV定位矩阵是评估克拉伯氏症治疗市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商,从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商,以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议:制定克拉伯氏症治疗市场的成功之路

对于旨在加强在全球市场的影响力的公司来说,克拉伯氏症治疗市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标,公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战,利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1. 市场渗透率:详细检视当前市场环境,主要企业的广泛资料,评估其在市场中的影响力和整体影响力。

2. 市场开拓:辨识新兴市场的成长机会,评估现有细分市场的扩张潜力,并提供未来成长的策略蓝图。

3. 市场多元化:分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报:彻底分析竞争格局,检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新:重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

它也回答重要问题,帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少?

2. 哪些产品和地区提供最佳投资机会?

3.塑造市场的关键技术趋势和监管影响是什么?

4.主要厂商的市场占有率和竞争地位如何?

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么?

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 克拉伯氏症的发生率在全球范围内增加
      • 增加基因治疗和干细胞移植研究
      • 政府和私人倡议提高人们对遗传疾病的认识
    • 抑制因素
      • 治疗克拉伯氏症的高昂费用
    • 机会
      • 克拉伯氏症的诊断和治疗进展
      • 扩大克拉伯氏症研究的有利资金筹措状况
    • 任务
      • 克拉伯氏症检测与治疗的伦理问题
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章克拉伯氏症治疗市场:依疾病类型

  • 介绍
  • 幼儿期
  • 后天性

第七章克拉伯氏症治疗市场:依治疗分类

  • 介绍
  • 抗惊厥药
  • 骨髓移植
  • 肌肉鬆弛剂

第八章克拉伯氏症治疗市场:依通路

  • 介绍
  • 电子商务
  • 医院药房
  • 零售药房

第九章 美洲克拉伯氏症治疗市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太克拉伯症治疗市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲克拉伯病治疗市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵,2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Acorda Therapeutics Inc.
  • Apteeus SAS
  • Centogene NV
  • Forge Biologics, Inc.
  • Gain Therapeutics, Inc.
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • M6P Therapeutics
  • Neurogene Inc.
  • Novartis AG
  • Pfizer Inc.
  • Polaryx Therapeutics, Inc
  • Polpharma
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB Pharmaceuticals
Product Code: MRR-C002B1C9976C

The Krabbe Disease Treatment Market was valued at USD 1.72 billion in 2023, expected to reach USD 1.83 billion in 2024, and is projected to grow at a CAGR of 6.49%, to USD 2.68 billion by 2030.

Krabbe Disease, a rare and often fatal genetic disorder affecting the nervous system, is increasingly becoming a focal point in healthcare research due to its complexity and limited treatment options. The treatment landscape primarily involves the application of hematopoietic stem-cell transplantation (HSCT), enzyme replacement therapies, and gene therapies, yet the market necessity remains high due to the limited efficacy and availability of these treatments. This unmet need, combined with advancements in biotech and pharmaceuticals, has sparked interest in the development of more effective and accessible solutions. Key growth influencers include increasing awareness and diagnosis of the disease, advances in genetic research, and supportive government policies aimed at rare diseases. Latest opportunities lie in the progression of gene-editing technologies like CRISPR and novel drug formulations, providing potential for groundbreaking treatments and improved quality of life for patients. Nevertheless, the market faces significant challenges, including high R&D costs, regulatory complexities associated with rare diseases, and a limited patient pool, which can deter investment. To overcome these limitations, businesses can focus on collaborative research initiatives and partnerships with academic institutions, which can provide access to cutting-edge technology and shared resources. Innovative efforts in personalized medicine, particularly in tailoring treatments based on genetic profiles, represent an exciting area of potential growth and differentiation. The nature of the market remains both challenging and promising, characterized by rapid technological advances alongside logistical and financial hurdles. Successful market entries and leadership would likely require strategic investment in R&D, agile adaptation to emerging regulatory requirements, and a robust understanding of the patient journey to address critical unmet needs expertly. Engaging in continuous market research to monitor technological trends, policy shifts, and competitive movements will be essential for positioning and sustaining growth in the Krabbe Disease treatment market.

KEY MARKET STATISTICS
Base Year [2023] USD 1.72 billion
Estimated Year [2024] USD 1.83 billion
Forecast Year [2030] USD 2.68 billion
CAGR (%) 6.49%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Krabbe Disease Treatment Market

The Krabbe Disease Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of Krabbe disease worldwide
    • Rise in gene therapy and stem cell transplantation research
    • Government and private initiatives to raise awareness about inherited disorders
  • Market Restraints
    • High cost associated with treatment for Krabbe disease
  • Market Opportunities
    • Advancements in the diagnosis and treatment of Krabbe disease
    • Favorable funding landscape for expanding research on krabbe disease
  • Market Challenges
    • Ethical issues with testing and treatment for Krabbe disease

Porter's Five Forces: A Strategic Tool for Navigating the Krabbe Disease Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Krabbe Disease Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Krabbe Disease Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Krabbe Disease Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Krabbe Disease Treatment Market

A detailed market share analysis in the Krabbe Disease Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Krabbe Disease Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Krabbe Disease Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Krabbe Disease Treatment Market

A strategic analysis of the Krabbe Disease Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Krabbe Disease Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Acorda Therapeutics Inc., Apteeus SAS, Centogene N.V., Forge Biologics, Inc., Gain Therapeutics, Inc., GlaxoSmithKline Plc, Johnson & Johnson, M6P Therapeutics, Neurogene Inc., Novartis AG, Pfizer Inc., Polaryx Therapeutics, Inc, Polpharma, Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and UCB Pharmaceuticals.

Market Segmentation & Coverage

This research report categorizes the Krabbe Disease Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease Type, market is studied across Infantile and Late-onset.
  • Based on Treatment, market is studied across Anticonvulsant Agents, Bone Marrow Transplantation, and Muscle Relaxer Drugs.
  • Based on Distribution Channel, market is studied across E-commerce, Hospital Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of Krabbe disease worldwide
      • 5.1.1.2. Rise in gene therapy and stem cell transplantation research
      • 5.1.1.3. Government and private initiatives to raise awareness about inherited disorders
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with treatment for Krabbe disease
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in the diagnosis and treatment of Krabbe disease
      • 5.1.3.2. Favorable funding landscape for expanding research on krabbe disease
    • 5.1.4. Challenges
      • 5.1.4.1. Ethical issues with testing and treatment for Krabbe disease
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Krabbe Disease Treatment Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Infantile
  • 6.3. Late-onset

7. Krabbe Disease Treatment Market, by Treatment

  • 7.1. Introduction
  • 7.2. Anticonvulsant Agents
  • 7.3. Bone Marrow Transplantation
  • 7.4. Muscle Relaxer Drugs

8. Krabbe Disease Treatment Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. E-commerce
  • 8.3. Hospital Pharmacies
  • 8.4. Retail Pharmacies

9. Americas Krabbe Disease Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Krabbe Disease Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Krabbe Disease Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Acorda Therapeutics Inc.
  • 3. Apteeus SAS
  • 4. Centogene N.V.
  • 5. Forge Biologics, Inc.
  • 6. Gain Therapeutics, Inc.
  • 7. GlaxoSmithKline Plc
  • 8. Johnson & Johnson
  • 9. M6P Therapeutics
  • 10. Neurogene Inc.
  • 11. Novartis AG
  • 12. Pfizer Inc.
  • 13. Polaryx Therapeutics, Inc
  • 14. Polpharma
  • 15. Sanofi S.A.
  • 16. Takeda Pharmaceutical Company Limited
  • 17. Teva Pharmaceutical Industries Ltd.
  • 18. UCB Pharmaceuticals

LIST OF FIGURES

  • FIGURE 1. KRABBE DISEASE TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. KRABBE DISEASE TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS KRABBE DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS KRABBE DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES KRABBE DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES KRABBE DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC KRABBE DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC KRABBE DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA KRABBE DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA KRABBE DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. KRABBE DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. KRABBE DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. KRABBE DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. KRABBE DISEASE TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY INFANTILE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY LATE-ONSET, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY ANTICONVULSANT AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY MUSCLE RELAXER DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY E-COMMERCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS KRABBE DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES KRABBE DISEASE TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC KRABBE DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA KRABBE DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. KRABBE DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 146. KRABBE DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023